Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.33), versus ($0.32) reported last year. Revenue for the quarter came in at $2.2 million, versus $592 thousand reported last year.

For earnings history and earnings-related data on Celldex (CLDX) click here.

Earnings

Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay August 11, 2015 10:10 AM Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on WeaknessAugust 11, 2015 8:11 AM Brean Capital Cuts Price Target on Celldex (CLDX) Following Talks with FDA August 11, 2015 7:07 AM Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update August 11, 2015 6:58 AM Celldex Reports Second Quarter 2015 ResultsAugust 10, 2015 4:01 PM